HighTower Advisors LLC Buys New Position in OrthoPediatrics Corp. (NASDAQ:KIDS)

HighTower Advisors LLC bought a new position in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,551 shares of the company's stock, valued at approximately $268,000.

Several other institutional investors and hedge funds also recently modified their holdings of KIDS. Charles Schwab Investment Management Inc. raised its holdings in shares of OrthoPediatrics by 2.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 132,434 shares of the company's stock worth $3,590,000 after acquiring an additional 2,661 shares during the last quarter. Quantbot Technologies LP raised its stake in OrthoPediatrics by 42.2% in the 3rd quarter. Quantbot Technologies LP now owns 5,773 shares of the company's stock valued at $157,000 after purchasing an additional 1,712 shares during the last quarter. BNP Paribas Financial Markets raised its stake in OrthoPediatrics by 125.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company's stock valued at $94,000 after purchasing an additional 1,929 shares during the last quarter. Centiva Capital LP purchased a new position in OrthoPediatrics in the 3rd quarter valued at about $319,000. Finally, Portolan Capital Management LLC boosted its stake in shares of OrthoPediatrics by 66.2% during the 3rd quarter. Portolan Capital Management LLC now owns 308,099 shares of the company's stock worth $8,353,000 after purchasing an additional 122,770 shares during the last quarter. Hedge funds and other institutional investors own 69.05% of the company's stock.

OrthoPediatrics Trading Down 4.0 %

KIDS stock traded down $0.90 on Monday, hitting $21.80. 416,799 shares of the company were exchanged, compared to its average volume of 201,390. The stock has a market capitalization of $529.46 million, a price-to-earnings ratio of -17.72 and a beta of 1.17. The business's fifty day moving average is $24.42 and its two-hundred day moving average is $24.92. OrthoPediatrics Corp. has a twelve month low of $21.02 and a twelve month high of $35.99. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68.

Remove Ads

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.04. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The business had revenue of $52.67 million during the quarter, compared to the consensus estimate of $51.16 million. During the same period in the prior year, the firm posted ($0.23) EPS. As a group, research analysts forecast that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Insider Activity

In other news, General Counsel Daniel J. Gerritzen sold 5,310 shares of the firm's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $132,006.60. Following the transaction, the general counsel now owns 110,767 shares of the company's stock, valued at approximately $2,753,667.62. This trade represents a 4.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Gregory A. Odle sold 5,359 shares of OrthoPediatrics stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $133,224.74. Following the transaction, the insider now owns 148,788 shares in the company, valued at $3,698,869.68. The trade was a 3.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,732 shares of company stock valued at $589,978 in the last three months. Corporate insiders own 31.80% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Truist Financial cut their price objective on shares of OrthoPediatrics from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Wednesday, December 18th. Stifel Nicolaus cut their price target on OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, March 5th. Lake Street Capital initiated coverage on OrthoPediatrics in a research note on Monday. They set a "buy" rating and a $37.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $42.00 price objective on shares of OrthoPediatrics in a research report on Wednesday, March 5th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, OrthoPediatrics presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.20.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.